Compare Agilent Technologies Inc (A) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs TG Therapeutics Inc — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.22B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Agilent Technologies Inc is far larger — about 5.5× TG Therapeutics Inc's market cap, and Agilent Technologies Inc pays a 0.68% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| A | TGTX | |
|---|---|---|
Market Cap | $42.22B | $7.64B |
Sector | Health | Health |
52-Week High | $157.20 | $59.06 |
52-Week Low | $110.24 | $26.94 |
Enterprise Value | $43.77B | $7.84B |
Dividend Yield | 0.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $148.23, near its consensus price target of $154.90, with a slight 0.33% decline over 24 hours. The stock shows strong fundamentals, including a 19.55% net income margin and robust ROE of 21.33%, while technical indicators signal a bullish trend despite overbought RSI levels. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, reinforcing growth in biopharma services.
Outlook remains positive with 77.5% analyst buy ratings, but risks include high valuation multiples (P/E 30.02) and dependence on healthcare spending. Earnings beat in Q1 2026 supports upside, though Q2 2026 results due August 26 are critical for momentum. Institutional accumulation, like Ashton Thomas Securities' 47.1% stake increase in Q2 2026, underscores confidence.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
